prikaz prve stranice dokumenta PCSK9 inhibitors in clinical practice: Expectations and reality
Pristup korisnicima matične ustanove
Znanstveni rad - Ostalo
PCSK9 inhibitors in clinical practice: Expectations and reality
Atherosclerosis (Amsterdam), 270 (2018); 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001
Reiner, Željko

Citirajte ovaj rad

Reiner, Ž. (2018). PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis (Amsterdam), 270., 187-188. doi: 10.1016/j.atherosclerosis.2018.01.001

Reiner, Željko. "PCSK9 inhibitors in clinical practice: Expectations and reality." Atherosclerosis (Amsterdam), vol. 270, 2018, str. 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001

Reiner, Željko. "PCSK9 inhibitors in clinical practice: Expectations and reality." Atherosclerosis (Amsterdam) 270 (2018): 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001

Reiner, Ž. (2018) 'PCSK9 inhibitors in clinical practice: Expectations and reality', Atherosclerosis (Amsterdam), 270, str. 187-188. doi: 10.1016/j.atherosclerosis.2018.01.001

Reiner Ž. PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis (Amsterdam) [Internet]. 2018. [pristupljeno 23.04.2024.];270:187-188. doi: 10.1016/j.atherosclerosis.2018.01.001

Ž. Reiner, "PCSK9 inhibitors in clinical practice: Expectations and reality", Atherosclerosis (Amsterdam), vol. 270, str. 187-188, 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:226642. [Citirano: 23.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:226642
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)PCSK9 inhibitors in clinical practice: Expectations and reality
AutorŽeljko Reiner
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
There is no doubt today that lowering LDL- cholestrol (LDL-C) reduces atherosclerotic cardiovascular disease (ASCVD) morbidity and mortality [1]. Statins are the established treatment of choice for lowering LDL-C since the early 90s and in secondary, but also primary prevention, they can reduce ASCVD morbidity and mortality [2]. Nevertheless, a number of patients, particularly those with familial hypercholesterolaemia (FH), are unable to achieve LDL-C target values, as recommended by the guidelines, even with high doses of more potent statins [3–5].
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Ostalo
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaAtherosclerosis (Amsterdam)
Brojčani podacivol. 270, str. 187-188
p-ISSN0021-9150
DOIhttps://doi.org/10.1016/j.atherosclerosis.2018.01.001
URN:NBNurn:nbn:hr:184:226642
Datum objave publikacije2018
URL dokumentahttp://bib.irb.hr/1049922
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-03-01 14:46:47